MARKET

VAXX

VAXX

Vaxxinity, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
-0.030
-1.69%
Opening 12:12 07/06 EDT
OPEN
1.760
PREV CLOSE
1.770
HIGH
1.830
LOW
1.700
VOLUME
114.80K
TURNOVER
152.59K
52 WEEK HIGH
22.77
52 WEEK LOW
1.510
MARKET CAP
219.23M
P/E (TTM)
-2.2536
1D
5D
1M
3M
1Y
5Y
Insiders Buy More Than $21M Of 3 Penny Stocks
U.S. stocks traded slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested ...
Benzinga · 06/22 17:26
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/22 12:55
Insider Buy: Vaxxinity
MT Newswires · 06/21 17:17
Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers' pack
Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Technologies (A...
Seekingalpha · 06/16 14:08
Vaxxinity to Participate at the Jefferies Healthcare Conference
DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will part...
GlobeNewswire · 06/02 11:00
FUV, ATNF and LOV among mid-day movers
Gainers: Tonix Pharmaceuticals Holding (TNXP) +60%. Helius Medical Technologies (HSDT) +40%. View (VIEW) +42%. Spark Networks (LOV) +32%. Regencell Bioscience Holdings (RGC) +21%. 180 Life Sciences (ATNF) +20%. Evelo Biosciences
Seekingalpha · 06/01 17:13
--Vaxxinity Shares Rally 17% Amid Moderate Trading Volume, Reaching Three-Week High
MT Newswires · 06/01 14:38
What Percentage Of Vaxxinity, Inc. (NASDAQ:VAXX) Shares Do Insiders Own?
Every investor in Vaxxinity, Inc. ( NASDAQ:VAXX ) should be aware of the most powerful shareholder groups. Generally...
Simply Wall St. · 05/12 13:31
More
No Data
Learn about the latest financial forecast of VAXX. Analyze the recent business situations of Vaxxinity, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VAXX stock price target is 15.00 with a high estimate of 18.00 and a low estimate of 12.00.
High18.00
Average15.00
Low12.00
Current 1.760
EPS
Actual
Estimate
-0.29-0.22-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 12
Institutional Holdings: 19.62M
% Owned: 15.57%
Shares Outstanding: 125.99M
TypeInstitutionsShares
Increased
1
15.66K
New
1
10.77K
Decreased
6
171.06K
Sold Out
6
141.16K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+0.37%
Key Executives
Director
Gregory R. Blatt
Chief Medical Officer
Ulo Palm
Chief Scientific Officer
Farshad Guirakhoo
General Counsel and Secretary
René Paula Molina
Co-Founder and Executive Chairman of the Board
Louis Reese
Interim Chief Financial Officer, Treasurer and Principal Accounting Officer
Martin Doran
Director
James Chui
Co-Founder, President, Chief Executive Officer and Director
Mei Mei Hu
Director
Peter Diamandis
No Data
No Data
About VAXX
Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.

Webull offers kinds of Vaxxinity Inc stock information, including NASDAQ:VAXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VAXX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VAXX stock methods without spending real money on the virtual paper trading platform.